Neumora Therapeutics (NMRA) — Stock, Pipeline & Market Cap

Is this your company? Claim your profile to update info and connect with investors.

Claim profile

NMRA · Stock Price

USD 2.33+1.69 (+264.63%)

Market Cap: $369.0M

Historical price data

Market Cap: $369.0MPipeline: 7 drugs (4 Phase 3)Patents: 19Founded: 2019Employees: 100-250HQ: Watertown, United States

Sector Ranking#26 in AI / Machine Learning #40 in Neuroscience & CNS

Overview

Neumora Therapeutics is a clinical-stage biotech company founded in 2019 with a mission to revolutionize neuroscience drug development through data-driven precision medicine. Its core strategy involves using a proprietary platform to identify biologically defined patient populations and advance a pipeline of novel, best-in-class therapeutics for major depressive disorder, schizophrenia, Alzheimer's agitation, and Parkinson's disease. The company's lead asset, navacaprant, is a novel kappa opioid receptor antagonist in Phase 3 development for MDD, representing a significant near-term catalyst.

NeuropsychiatryNeurodegeneration

Technology Platform

A proprietary, data-driven 'Precision Toolbox' that integrates multi-modal biomarker data (genomics, neuroimaging, electrophysiology) with advanced computational analytics to deconvolve disease heterogeneity and enable precision medicine approaches in neuroscience.

Pipeline

7

7 drugs in pipeline4 in Phase 3

Drug	Indication	Stage
NMRA-335140	Major Depressive Disorder	Phase 3
NMRA-335140 + Placebo	Major Depressive Disorder	Phase 3
NMRA-335140 + Placebo	Major Depressive Disorder	Phase 3
NMRA-335140 + Placebo	Major Depressive Disorder	Phase 3
NMRA-335140 80 mg + Placebo	Major Depressive Episode Associated With Bipolar II Disorder	Phase 2

Funding History

1

Total raised:$112M

Series B$112MUndisclosedOct 11, 2022

Opportunities

The primary opportunity is the vast, underserved market for brain diseases, where precision medicine approaches could command premium pricing.

Near-term, success of the lead Phase 3 asset, navacaprant, in MDD could create a multi-billion dollar product and validate the company's entire platform.

Risk Factors

High clinical failure risk, particularly for the pivotal Phase 3 trial of navacaprant.

The company's novel data-driven platform remains unproven in late-stage trials.

Intense competition and future capital needs pose additional significant risks.

Competitive Landscape

Neumora faces intense competition in all its therapeutic areas but differentiates through novel mechanisms (e.g., KOR, M4) and a precision medicine strategy. Its lead asset competes in the crowded MDD space, while its earlier-stage programs target specific mechanistic niches with less direct competition.